ClinicalTrials.gg
CompletedNCT00337649Updated Apr 28, 2023

A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer

A Phase 1/2 interventional study of Epothilone D and Herceptin in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-28.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing desoxyepothilone B in Breast Neoplasms — 8 open to participants now, 9 under way, 4 of them phase 3. desoxyepothilone B · Breast Neoplasms.

Enrollment
13th of 14
27 · median 110
Started
2004
the only one that year
Phase 1/2
Only one
of the 14
Registered
1st of 14
by date
Lead sponsor
1 of 14
Hoffmann-La Roche

Among the 14 studies testing desoxyepothilone B in Breast Neoplasms, this one is the 13th largest by enrollment, is the only one that started in 2004, is the only one in phase 1/2, and was the 1st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing desoxyepothilone B in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About desoxyepothilone B

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing desoxyepothilone B in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm study will determine the efficacy and safety of an epothilone D and Herceptin combination regimen in patients with HER-2 positive locally advanced or metastatic breast cancer. Epothilone D will be administered intravenously on days 1, 8 and 15 every 4 weeks at a dose not exceeding 100mg/m2. Herceptin will be administered intravenously on a weekly schedule; a 4mg/kg loading dose will be followed by a weekly maintenance dose of 2mg/kg. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women >=18 years;
  • locally advanced or breast cancer;
  • overexpression (FISH + or IHC 3+);
  • >=1 ;
  • up to one prior anthracycline-based chemotherapy regimen in a metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • pre-existing neuropathy >=grade 2;
  • known ;
  • congestive heart failure, or myocardial infarction within the last 6 months;
  • previous in last 5 years, except for cured basal cell cancer of the skin, or cancer in situ of the cervix.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Phase I - Epothilone D Dose Escalation

    Drug: Epothilone D · Drug: Herceptin

  • Experimental
    Phase II - Epothilone D Maximum Tolerated Dose

    Drug: Epothilone D · Drug: Herceptin

Interventions

  • ≤100 mg/m\^2 intravenously (iv) on days 1, 8 and 15 once every 4 weeks

    Also known as: RO4598715, KOS-862

  • 4mg/kg iv loading dose, followed by 2mg/kg iv weekly

    Also known as: Trastuzumab

06

What researchers measure

Primary outcomes

  1. Phase I: Number of Participants with a Dose-Limiting Toxicity

    Time frame: From first dose of study treatment until end of Cycle 1 (1 cycle is 28 days)

  2. Phase II: Objective Response Rate (per RECIST criteria)

    Time frame: From first dose of study treatment until documented response (up to 3 years, 2 months)

Secondary outcomes

  1. Phase II: Duration of Response

    Time frame: From date of objective response until progressive disease or death, whichever occurs first (up to 3 years, 2 months)

  2. Phase II: Time to Tumor Progression

    Time frame: From first dose of study treatment until progressive disease or death, whichever occurs first (up to 3 years, 2 months)

  3. Phase I: Plasma Concentration of Epothilone D at Specified Timepoints

    Time frame: Cycle 1 Days -2, -1, and 1; Cycle 2 Days 1 15-17 (1 cycle is 28 days)

  4. Number of Participants with at Least One Adverse Event

    Time frame: From first dose of study treatment until 28 days after last dose (up to 3 years, 2 months)

07

Study locations

6 sites
  • Barcelona, 08035, Spain
  • Barcelona, 08036, Spain
  • Barcelona, 08041, Spain
  • Madrid, 28041, Spain
  • Valencia, 46009, Spain
  • Valencia, 46010, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Jul 2007 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2006
First posted
Jun 16, 2006
Start
May 2004
Primary completionActual
Jul 2007
CompletionActual
Jul 2007
Last update
Apr 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00337649
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 16, 2006
Start date
May 2004
Primary completion
Jul 2007
Completion
Jul 2007
Last update
Apr 28, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desoxyepothilone B

Start the discussion